Oncolytics Biotech Inc T.ONC

Some numbers to chew on….Roche & onc

[canadafan]

I did some digging.
Roche annual sales of Tecentriq is about $3billion/ year.
They do not presently deal in Pancreatic cancer....hence the importance of the Goblet trial.
 Assuming , adding Pancreatic cancer to Roche catalog of cancer treatments: 
Could that double their market of tecentriq?
AKA $ 3 billion/ year in sales?
RBC has used $5billion/ year in their estimates for Pela & Mbc 
What would a corporation pay $$$ for a product which would:
1. Add a whole new market area ( pancreatic cancer)
2. Increase sales of their existing blockbuster tecentriq.
3. profits from Pela itself.
4. wide open estimates of the MBc market, CAR-T , exitsting trials showing good results with M.M.
Development & approval costs of drugs are huge.
Manufacturing & production costs per unit, once in place, very small.
point being the gross margins are huge.
Imho 
That math is what is driving the SP of Onc.
Should the next results out of Goblet, come close to the preliminary pancreatic cancer ( 3x standard of care) & a complete response with one......That would elevate Pela/ Tecentriq combo to blockbuster status.
It took Onc years to get FDA fast track approvals for the MBc use.
it took less than 3 months for the Panc results to be elevated & recognized.
Those who are getting all excited over a few spikes in the SP, need to appreciate the upside potential.
Adding to that, timelines.
roche or any pharma would be viewed globally as a huge win, bringing a drug to market for pancreatic cancer.
Some keep pointing at the trading share price as if it was/ is an indicator of something, or anything?
We know there are those who work real hard at pointing out any negative they can think of.
As I said before, Not one person posting here or any site including myself really know what is being discussed in the corporate board rooms.
Dig a little & very strong clinical evidence comes forward.
THAT is what matters.
The compnay vallue & SP will align with the science. Before the end of this year.
Few appreciate, the longer the patients live, the longer the results take. A troubling paradox.

[westcoast1000]

Thanks for the info on tecentriq, CF. Here are a few further points. Tencentriq in licensed for use in a variety of cancers already. It is possible that pela could help improve outcomes in an array of them. Also, there is an additional point to stress about timing. Not only are the results likely to be stronger the longer the results take for OS in panc and mBC, the higher value the company. The

[JohnnyYeg]

VERY well put Westie!!

[fox7mf]

Who knows why we are waiting, but it's obvious patience is wearing thin. This story ends in 2023 for me, one way or another.